Full-Time

IT Operations Engineer

Posted on 10/29/2024

Vaxcyte

Vaxcyte

201-500 employees

Develops vaccines for bacterial infections

Compensation Overview

$108k - $144k/yr

Senior

San Carlos, CA, USA

The job is onsite in San Carlos, CA.

Category
IT Support
IT & Security
Required Skills
Customer Service
Requirements
  • Minimum of 5+ years of experience in IT Support.
  • Demonstrated experience in IT operations or technical support roles, ideally in a mid-sized or large organization, with a strong focus on customer service.
  • Proven ability to provide friendly and effective remote and onsite support, resolving issues in a way that prioritizes user satisfaction.
  • Proficiency in Windows-based environments, troubleshooting hardware and software for end users.
  • Experience supporting Microsoft 365 suite, including Outlook, Office 365, Teams, etc., with a customer-first approach.
  • Experience with Okta for user management and identity authentication.
  • Experience with Intune or similar MDM solutions.
  • Basic knowledge of networking fundamentals (e.g., VPNs, Wi-Fi) to support end-user connectivity.
  • Familiarity with ticketing systems like Freshservice or similar, with a focus on user satisfaction.
  • Ability to maintain and troubleshoot conference room A/V equipment.
  • Ability to write clear and user-friendly documentation, including knowledge base articles and how-to guides.
  • Experience in customer-facing IT support roles, providing excellent service to both remote and onsite users.
  • Strong customer service skills, with the ability to handle issues in a professional and friendly manner.
  • Excellent communication skills to interact effectively with both technical and non-technical users.
  • Strong troubleshooting and problem-solving skills.
  • Strong organizational and documentation skills.
  • Ability to collaborate effectively on cross-functional projects and initiatives, contributing to the broader IT strategy.
Responsibilities
  • Deliver exceptional customer service while providing technical support, ensuring users feel supported and satisfied with the resolution process.
  • Respond to and resolve IT tickets for both onsite and remote users, addressing hardware, software, and network-related issues.
  • Handle IT tickets via Freshservice, ensuring quick and efficient resolutions to a range of technical issues.
  • Manage and troubleshoot user accounts through Okta, supporting identity and access needs.
  • Provide customer-focused support for Microsoft 365 applications, including Outlook, Office 365, Teams, and more.
  • Manage, troubleshoot, and support Windows desktops and laptops, ensuring users’ devices function optimally.
  • Use Intune to manage mobile devices, focusing on customer satisfaction while ensuring device security.
  • Perform basic network diagnostics and troubleshooting for onsite and remote employees.
  • Maintain and troubleshoot conference room A/V equipment.
  • Assist with setup, configuration, and troubleshooting of IT hardware such as desktops, laptops, and peripherals.
  • Install and maintain software, providing guidance and support to users throughout the process.
  • Collaborate with the IT Systems Engineering group to support cross-functional projects and initiatives, contributing technical expertise.
  • Create and maintain user-friendly documentation, including knowledge base articles and how-to guides, ensuring users and IT staff can easily follow instructions.
Desired Qualifications
  • Hands-on experience in biotech or similarly regulated industries is a plus.
  • Certifications such as CompTIA A+, Network+, or Microsoft certifications are valued but not required.

Vaxcyte develops vaccines aimed at preventing bacterial infections, focusing on diseases like invasive pneumococcal disease, Group A Strep, periodontitis, and Shigella. Their lead product, VAX-24, is a pneumococcal conjugate vaccine that targets 24 strains of the Streptococcus pneumoniae bacteria and has received Breakthrough Therapy designation from the FDA. Vaxcyte utilizes advanced chemistry and a proprietary cell-free protein synthesis platform, XpressCF™, to create vaccines that can effectively address the complex defenses of bacteria while stimulating an immune response. This method sets them apart from traditional cell-based vaccine production. The company's goal is to develop and commercialize broad-spectrum vaccines to improve public health and combat serious bacterial infections.

Company Size

201-500

Company Stage

IPO

Headquarters

Foster City, California

Founded

2013

Simplify Jobs

Simplify's Take

What believers are saying

  • Vaxcyte's VAX-24 has FDA Breakthrough Therapy designation for pneumococcal disease prevention.
  • Recent $1.5 billion public offering boosts Vaxcyte's financial resources for vaccine development.
  • Growing antibiotic resistance increases demand for Vaxcyte's novel bacterial vaccines.

What critics are saying

  • Competition from mRNA vaccine developers like Moderna and BioNTech is intense.
  • Supply chain vulnerabilities could disrupt Vaxcyte's proprietary XpressCF™ platform.
  • Emerging bacterial strains may not be covered by Vaxcyte's current vaccine candidates.

What makes Vaxcyte unique

  • Vaxcyte uses a proprietary cell-free protein synthesis platform, XpressCF™, for vaccine development.
  • Their lead product, VAX-24, targets 24 strains of Streptococcus pneumoniae.
  • Vaxcyte's vaccines aim to combat bacterial infections, including pneumococcal disease and Group A Strep.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Company Equity

Stock Options

Remote Work Options

Growth & Insights and Company News

Headcount

6 month growth

-2%

1 year growth

0%

2 year growth

-1%
Clinical Trial Vanguard
Mar 31st, 2025
Vaxcyte Announces Positive VAX-24 Infant Phase 2 Results

Vaxcyte aims to develop superior vaccines against bacterial diseases, utilizing advanced synthetic techniques like their XpressCF(TM) cell-free protein synthesis platform.

MarketBeat
Oct 5th, 2024
Clearbridge Investments LLC Makes New $14.06 Million Investment in Vaxcyte, Inc. (NASDAQ:PCVX)

Clearbridge Investments LLC makes new $14.06 million investment in Vaxcyte, Inc. (NASDAQ:PCVX).

Bizjournals
Sep 20th, 2024
Winner, Public Company, Small: Andrew Guggenhime, Vaxcyte Inc.

In the early weeks of the Covid-19 pandemic, Andrew Guggenhime joined San Carlos-based Vaxcyte Inc. as chief financial officer and chief operating officer, drawn by the company's mission to develop vaccines to prevent and treat infectious bacterial diseases.

Yahoo Finance
Sep 9th, 2024
Vaxcyte Announces Pricing of $1.3 Billion Public Offering

SAN CARLOS, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today the pricing of an underwritten public offering of common stock and pre-funded warrants. Vaxcyte is selling 10,194,175 shares of common stock and pre-funded warrants to purchase 2,427,184 shares of common stock in the offering. The shares of common stock

Vaxcyte
Sep 6th, 2024
Vaxcyte Announces Closing of $1.5 Billion Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Vaxcyte announces closing of $1.5 billion public offering including full exercise of underwriters' option to purchase additional shares.

INACTIVE